Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Ravicti in Urea Cycle Disorders
NCT01257737Phase 4Completed
- Sponsor
- Amgen
- Start
- Oct 2010
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of sodium phenylbutyrate in urea cycle disorders (UCD), sponsored by Amgen. Primary endpoint: Number of Participants With at Least One Adverse Event up to 66 months. Started Oct 2010; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
urea cycle disorders (UCD)
Beyond the preview
Go deeper on NCT01257737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01257737.